CR, sorafenib vs. placebo → 48% vs. 60% (p = 0.12)ORR, 57% vs. 64% (p = 0.34)In FLT3-ITD+, CR 40% vs. 72% (NS)Overally, median EFS, 5 vs. 7 mo (p = 0.88)Median OS 13 vs. 15 mo (p = 0.12)→ standard CTx with sorafenib, not beneficial in elderly AML pts. The gene discussed is FLT3; the disease is acute myeloid leukemia.